Résumé
Several direct oral anticoagulants (DOACs) are now widely used in the prevention and treatment of thromboembolic events. Unlike vitamin K antagonists, DOACs exhibit predictable pharmacokinetics and pharmacodynamics. DOACs are to be administered at fixed doses without routine coagulation monitoring. However, in some patient populations or specific clinical circumstances, measurement of drug exposure may be useful, such as in suspected overdose, in patients with a haemorrhagic or thromboembolic event during treatment with an anticoagulant, in those with acute renal failure, or in patients who require urgent surgery. This article provides practical guidance on laboratory testing of DOACs in routine practice and summarizes the influence of DOACs on commonly used coagulation assays.
Titre traduit de la contribution | Why, when and how monitor new oral anticoagulants? |
---|---|
langue originale | Français |
Pages (de - à) | 326-333 |
Nombre de pages | 8 |
journal | Revue médicale suisse |
Volume | 10 |
Numéro de publication | 416 |
Etat de la publication | Publié - 5 févr. 2014 |
Empreinte digitale
Examiner les sujets de recherche de « Pourquoi, quand et comment doser les nouveaux anticoagulants oraux? ». Ensemble, ils forment une empreinte digitale unique.Thèses de l'étudiant
-
Evaluation of thrombotic and/or bleeding risks associated with anticoagulotherapy.
Douxfils, J. (Auteur)Dogne, J.-M. (Promoteur), Mullier, F. (Promoteur), Masereel, B. (Président), Chatelain, B. (Jury), Chatelain, C. (Jury), Verhamme, P. (Jury), TEN CATE, H. (Jury) & Ageno, W. (Jury), 24 oct. 2015Student thesis: Doc types › Docteur en Sciences Biomédicales et Pharmaceutiques